Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

510
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
510
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

11.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.3K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

2.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing the challenges of immunogenicity, heterogeneity and tumorigenicity in the clinical translation of human embryonic stem cells.

Stem cell research & therapy·2025
Same author

Correction to "Insights into the Activation Mechanism of HCA1, HCA2, and HCA3".

Journal of medicinal chemistry·2025
Same author

A machine learning protocol for predicting structural distributions of amyloid-forming proteins from 2D IR spectra.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Beyond the melting point annealing of poly(vinylidene fluoride) for enhanced piezoelectric performance.

Materials horizons·2025
Same author

A liver abscess caused by <i>Aeromonas dhakensis</i> after the consumption of freshwater fish: A case report and literature review.

IDCases·2025
Same author

Substantial planar plastic anisotropy in inorganic Mg<sub>3</sub>Bi<sub>2</sub> single crystals.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same journal

TIM3 alleviates microglia-mediated neuroinflammation in neuropathic pain by negatively regulating glycolysis-driven NLRP3 inflammasome activation.

Acta biochimica et biophysica Sinica·2026
Same journal

Phillyrin protects against myocardial ischemia/reperfusion injury by promoting KNL1 K605 acetylation to inhibit the p53/p21 pathway.

Acta biochimica et biophysica Sinica·2026
Same journal

A bifunctional aptamer-siRNA chimera targeting ACE2 for the inhibition of SARS-CoV-2 S pseudovirus entry and replication.

Acta biochimica et biophysica Sinica·2026
Same journal

Tryptophan-substituted antimicrobial peptide temporin-1CEb: <i>in vitro</i> and <i>in vivo</i> antibacterial activity against clinically isolated multidrug-resistant <i>Klebsiella pneumonia</i>.

Acta biochimica et biophysica Sinica·2026
Same journal

Ribosomal protein L8 promotes melanoma progression by regulating the cell cycle and metastasis.

Acta biochimica et biophysica Sinica·2026
Same journal

Bioinformatics classification of the MgtE Mg <sup>2</sup> <sup>+</sup> channel and <i>de novo</i> protein design for the stabilization of its novel subclass.

Acta biochimica et biophysica Sinica·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

Novel FGF21 analogues through structure-based optimization for therapeutic development.

Yiqing Guo1, Yuxuan Bao2, Zhichao Chen2

  • 1Frontiers Science Center for Synthetic Biology (Ministry of Education), Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, School of Life Sciences, Tianjin University, Tianjin 300072, China.

Acta Biochimica Et Biophysica Sinica
|December 25, 2024
PubMed
Summary
This summary is machine-generated.

Researchers developed long-acting Fibroblast Growth Factor 21 (FGF21) analogs by fusing FGF21 with an Fc fragment. These novel analogs show enhanced potency, offering potential new treatments for obesity and related metabolic disorders.

Keywords:
fibroblast growth factor 21 (FGF21)metabolic diseasesprotein engineeringsequence analysis

More Related Videos

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.7K
Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

5.0K

Related Experiment Videos

Last Updated: Jun 4, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.7K
Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

5.0K

Area of Science:

  • Metabolic Research
  • Protein Engineering
  • Pharmacology

Background:

  • Fibroblast Growth Factor 21 (FGF21) is crucial for metabolic regulation and energy balance.
  • Current FGF21 therapies are limited by suboptimal pharmacokinetics and bioactivity.
  • Obesity-related metabolic disorders represent a significant unmet medical need.

Purpose of the Study:

  • To engineer long-acting FGF21 analogs with improved therapeutic potential.
  • To enhance the potency and pharmacokinetic profile of FGF21.
  • To identify specific amino acid modifications for augmented FGF21 activity.

Main Methods:

  • Sequence alignment and comparative analysis to identify key amino acid residues.
  • Genetic engineering to create mutant FGF21 analogs.
  • Fusion of mutant FGF21 with the Fc fragment to improve pharmacokinetics.
  • Characterization of Fc-fused FGF21 analogs for potency and bioactivity.

Main Results:

  • Two distinct Fc-fused FGF21 analogs, Fc-FGF21(P119R) and Fc-FGF21(H125R), were successfully designed and identified.
  • These analogs demonstrated significantly augmented potency compared to wild-type FGF21.
  • The Fc fusion strategy enhanced the pharmacokinetic properties of the FGF21 analogs.

Conclusions:

  • Fc-fused FGF21 analogs represent a promising strategy for developing effective treatments for metabolic disorders.
  • The engineered analogs offer enhanced potency and improved pharmacokinetic profiles.
  • These findings support the clinical development of novel FGF21-based therapies for obesity and related conditions.